Although this could indicate a preferential recruitment of CD4 T cells in the inflamed tissues tested, the result has to be interpreted with caution due to the lack of statistical significance, the small sample size and the differing patient characteristics between the two groups tested, e.g., secondary acute bronchopneumonia in 2/5 and underlying neoplasms in 2/5 COVID-19 patients. The gene discussed is CD4; the disease is neoplasm.